MAPT and Alzheimer disease: Since brain insulin resistance contributes to AD development, increasing evidence suggests that peripheral type 2 diabetes mellitus (T2DM) may overlap and exacerbate AD-related cognitive impairment, neuroinflammation, oxidative stress, Aβ aggregation, tau hyperphosphorylation, and synaptic dysfunction [216,217,218].